Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash & Current Investments (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 7 years of Cash & Current Investments readings, the most recent being $468.1 million for Q1 2026.

  • On a quarterly basis, Cash & Current Investments rose 23.33% to $468.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $468.1 million, a 23.33% increase, with the full-year FY2025 number at $414.1 million, up 69.96% from a year prior.
  • Cash & Current Investments hit $468.1 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $414.1 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $468.1 million in Q1 2026 to a low of $182.1 million in Q2 2022.
  • Median Cash & Current Investments over the past 5 years was $243.6 million (2024), compared with a mean of $278.3 million.
  • Biggest five-year swings in Cash & Current Investments: plummeted 35.83% in 2022 and later skyrocketed 82.84% in 2024.
  • Kiniksa Pharmaceuticals International's Cash & Current Investments stood at $190.6 million in 2022, then grew by 8.27% to $206.4 million in 2023, then grew by 18.05% to $243.6 million in 2024, then skyrocketed by 69.96% to $414.1 million in 2025, then increased by 13.05% to $468.1 million in 2026.
  • The last three reported values for Cash & Current Investments were $468.1 million (Q1 2026), $414.1 million (Q4 2025), and $352.1 million (Q3 2025) per Business Quant data.